Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
27,027,085
-
Share change
-
-238,603
-
Total reported value
-
$612,383,000
-
Price per share
-
$22.74
-
Number of holders
-
50
-
Value change
-
-$9,657,853
-
Number of buys
-
28
-
Number of sells
-
17
Institutional Holders of ALIGOS THERAPEUTICS INC - COM NEW (ALGS) as of Q1 2021
As of 31 Mar 2021,
ALIGOS THERAPEUTICS INC - COM NEW (ALGS) was held by
50 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,027,085 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, Vivo Capital, LLC, Versant Venture Management, LLC, Novo Holdings A/S, JANUS HENDERSON GROUP PLC, HILLHOUSE CAPITAL ADVISORS, LTD., BAKER BROS. ADVISORS LP, BOXER CAPITAL, LLC, Cormorant Asset Management, LP, and Pivotal bioVenture Partners Investment Advisor LLC.
This page lists
50
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.